Kesimpta®
Quick Facts
Kesimpta® is a monoclonal antibody and anti-inflammatory disease-modifying therapy that depletes white blood cells called B cells.
Self-injected under the skin
Monthly
Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS
Potential Benefit:
Tested against active comparator, Kesimpta showed:
- Reduced relapse by 51%-59%
- Reduced likelihood of disability progression by 34%
- 94%-98% fewer Gd + T1 lesions on MRI
Common Potential Side Effects
Headache and upper respiratory tract infection (URTI), including sore throat, runny nose. Injection-related reactions (fever, headache, muscle pain, chills, and fatigue). Local injection site reactions (redness, pain, itching, and swelling).
Prescription Assistance:
For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.
DRUGMAKER
Novartis
HOW Kesimpta® WORKS
Kesimpta®, a monoclonal antibody, binds to a protein on the surface of immune cells, white blood cells called B lymphocytes or B cells. This depletes B cells, preventing them from stripping the myelin sheath and causing nerve damage.
FDA-Approved
Kesimpta® was FDA-approved in 2020 to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Potential Side Effects
Upper respiratory tract infection (URTI), including sore throat, runny nose, and headache, as well as headache unrelated to a URTI. Serious but less-common adverse events include infections, hepatitis B virus (HBV) reactivation, and a weakened immune system. A possible serious side effect is progressive multifocal leukoencephalopathy (PML), a rare brain infection that usually leads to death or severe disability over a period of weeks or months.
OTHER KEY INFORMATION
Testing completed prior to starting Kesimpta® includes:
- Perform hepatitis B virus (HBV) screening
- Test for quantitative serum immunoglobulins
- Consider: Complete Blood Count with differential, Comprehensive Metabolic Panel, T and B cell subset, QuantiFERON-TB Gold test, urinalysis and cultures
Testing completed after starting Kesimpta® includes:
- Complete Blood Count with differential, Comprehensive Metabolic Panel, T and B cell subset, immunoglobulins (IgG and IgM) every six months, consider urinalysis with culture and sensitivity